Chemotherapy plus immunotherapy for advanced squamous lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have histologically or cytologically confirmed advanced (stage IIIB–IV) squamous non-small cell lung cancer that is not eligible for surgery or radiation therapy
- You have not received any prior systemic (whole-body) cancer treatment for advanced disease, though prior adjuvant chemotherapy is allowed if progression occurred at least 6 months after treatment
- Your cancer does not have EGFR gene mutations or ALK gene fusions, or your gene status is unknown
- You have at least one measurable tumor lesion visible on imaging scans
- You have adequate organ function (normal blood counts, liver and kidney function, heart function, and thyroid function)
- You are between 18 and 75 years old with an ECOG performance status of 0–1 (able to perform daily activities with minimal restrictions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (sugemalimab) combined with chemotherapy as a first treatment for advanced non-small cell lung cancer. It aims to see if this combination works well in real-world patients.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
This Phase 2 study looks at how safe and effective serplulimab (an immune medicine) combined with chemotherapy is when used as a “conversion” plan—first shrinking lung cancer, then trying to remove the main tumor with surgery. It may help some people who are not initially good candidates for surgery or focused radiation to become eligible after treatment.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.